The Experts below are selected from a list of 114 Experts worldwide ranked by ideXlab platform
Squires R.a. - One of the best experts on this subject based on the ideXlab platform.
-
Recommendations on vaccination for Latin American small Animal practitioners: A report of the WSAVA Vaccination Guidelines Group
'Foundation for Cellular and Molecular Medicine', 2020Co-Authors: Day M.j., Crawford C., Marcondes M., Squires R.a.Abstract:The World Small Animal Veterinary Association Vaccination Guidelines Group has produced global guidelines for small companion Animal practitioners on best practice in canine and feline vaccination. Recognising that there are unique aspects of veterinary practice in certain geographical regions of the world, the Vaccination Guidelines Group undertook a regional project in Latin America between 2016 and 2019, culminating in the present document. The Vaccination Guidelines Group gathered scientific and demographic data during visits to Argentina, Brazil and Mexico, by discussion with national key opinion leaders, visiting veterinary practices and review of the scientific literature. A questionnaire survey was completed by 1390 veterinarians in five Latin American countries and the Vaccination Guidelines Group delivered continuing education at seven events attended by over 3500 veterinarians. The Vaccination Guidelines Group recognised numerous challenges in Latin America, for example: (1) lack of national oversight of the veterinary profession, (2) extraordinary growth in private veterinary schools of undetermined quality, (3) socioeconomic constraints on client engagement with preventive health care, (4) high regional prevalence of some key infectious diseases (e.g. feline leukaemia virus infection, canine visceral leishmaniosis), (5) almost complete lack of minimal antigen vaccine products as available in other markets, (6) relative lack of vaccine products with extended duration of immunity as available in other markets, (7) availability of vaccine products withdrawn from other markets (e.g. Giardia vaccine) or unique to Latin America (e.g. some Leishmania vaccines), (8) accessibility of vaccines directly by Pet owners or breeders such that vaccination is not delivered under veterinary supervision, (9) limited availability of continuing education in veterinary vaccinology and lack of compulsion for continuing professional development and (10) limited peer‐reviewed published scientific data on small companion Animal infectious diseases (with the exception of leishmaniosis) and lack of support for such academic research. In this document, the Vaccination Guidelines Group summarises the findings of this project and assesses in evidence‐based fashion the scientific literature pertaining to companion Animal vaccine‐preventable diseases in Latin America. The Vaccination Guidelines Group makes some recommendations on undergraduate and postgraduate education and academic research. Recognising that current product availability in Latin America does not permit veterinarians in these countries to vaccinate according to the global World Small Animal Veterinary Association guidelines, the Vaccination Guidelines Group makes a series of “pragmatic” recommendations as to what might be currently achievable, and a series of “aspirational” recommendations as to what might be desirable for the future. The concept of “vaccine husbandry” is addressed via some simple guidelines for the management of vaccine products in the practice. Finally, the Vaccination Guidelines Group emphasises the global trend towards delivery of vaccination as one part of an “annual health check” or “health care plan” that reviews holistically the preventive health care needs of the individual Pet Animal. Latin American practitioners should transition towards these important new practices that are now well embedded in more developed veterinary markets. The document also includes 70 frequently asked questions and their answers; these were posed to the Vaccination Guidelines Group during our continuing education events and small group discussions and should address many of the issues surrounding delivery of vaccination in the Latin American countries. Spanish and Portuguese translations of this document will be made freely available from the on‐line resource pages of the Vaccination Guidelines Group
-
Guidelines for the vaccination of dogs and cats compiled by the Vaccination Guidelines Group (VGG) of the World Small Animal Veterinary Association (WSAVA)
'Wiley', 2016Co-Authors: Day M.j., Horzinek M.c., Schultz R.d., Squires R.a.Abstract:The WSAVA Vaccination Guidelines Group (VGG) was convened in order to develop guidelines for the vaccination of dogs and cats that have global application. The first version of these guidelines was published in 2007 and they were updated in 2010. The present document provides a further updated and expanded version of these international guidelines for the vaccination of small companion Animals and indicates the scientific evidence base on which the recommendations are made. The VGG recognises that the keeping of Pet small Animals is subject to considerable variation in practice and associated economics throughout the world and that vaccination recommendations that might apply to a developed country may not be appropriate for a developing country. These guidelines are not a mandatory edict, but rather should be used by national associations and individual veterinary practices to develop vaccination schedules relevant locally. However, the VGG strongly recommends that wherever possible ALL dogs and cats receive the benefit of vaccination. This not only protects the individual Animal, but provides optimum ‘herd immunity’ that minimises the likelihood of infectious disease outbreaks. With this background in mind, the VGG has defined core vaccines as those which ALL dogs and cats, regardless of circumstances or geographical location, should receive. Core vaccines protect Animals from severe, life-threatening diseases that have global distribution. Core vaccines for dogs are those that protect against canine distemper virus (CDV), canine adenovirus (CAV) and the variants of canine parvovirus type 2 (CPV-2). Core vaccines for cats are those that protect against feline parvovirus (FPV), feline calicivirus (FCV) and feline herpesvirus-1 (FHV-1). In areas of the world where rabies virus infection is endemic, vaccination against this agent should be considered core for both species, even if there is no legal requirement for routine vaccination. The VGG recognizes that maternally-derived antibody (MDA) interferes with the efficacy of most current core vaccines administered to pups and kittens in early life. Because the level of MDA varies among litters, the VGG recommends administration of multiple core vaccine doses to pups and kittens, with the final dose given at 16 weeks or older and followed by a booster at 6- or 12-months of age. In cultural or financial situations where a Pet Animal may only be permitted the benefit of a single vaccination, that vaccination should be with core vaccines at 16 weeks of age or older. The VGG supports the use of simple in-practice tests for determination of seroconversion to the core vaccine components (CDV, CAV, CPV-2 and FPV) following vaccination, for determination of seroprotection in adult dogs and for management of infectious disease outbreaks in shelters. Vaccines should not be given needlessly. Core vaccines should not be given any more frequently than every three years after the 6- or 12-month booster injection following the puppy/kitten series, because the duration of immunity (DOI) is many years and may be up to the lifetime of the Pet. The VGG has defined non-core vaccines as those that are required by only those Animals whose geographical location, local environment or lifestyle places them at risk of contracting specific infections. The VGG has also classified some vaccines as not recommended (where there is insufficient scientific evidence to justify their use) and has not considered a number of minority products which have restricted geographical availability or application. The VGG strongly supports the concept of regular (usually annual) health checks which removes the emphasis from, and client expectation of, annual revaccination. The annual health check may still encompass administration of selected non-core vaccines which should be administered annually, as the DOI for these products is generally 1 year. The VGG has considered the use of vaccines in Animal shelters, again recognising the particular circumstances of such establishments and the financial constraints under which they sometimes operate. The VGG minimum shelter guidelines are simple: that all dogs and cats entering such an establishment should be vaccinated before, or at the time of entry, with core vaccines. Where finances permit, repeated core vaccines should be administered as per the schedules defined in the guidelines and non-core vaccines against respiratory disease may be included. The VGG recognizes the importance of adverse reaction reporting schemes, but understands that these are variably developed in different countries. Wherever possible, veterinarians should be actively encouraged to report all possible adverse events to the manufacturer and/or regulatory authority to expand the knowledge base that drives development of improved vaccine safety. These fundamental concepts proposed by the VGG may be encapsulated in the following statement: We should aim to vaccinate every Animal with core vaccines. Non-core vaccines should be given no more frequently than is deemed necessary
Norbert Mencke - One of the best experts on this subject based on the ideXlab platform.
-
establishment of the cat flea ctenocephalides felis felis on the ferret mustela putorius furo and its control with imidacloprid
Medical and Veterinary Entomology, 2001Co-Authors: M J Hutchinson, D E Jacobs, Norbert MenckeAbstract:As the ferret, Mustela putorius furo L. (Carnivora: Mustelidae), is becoming increasingly popular as a Pet Animal and as it is susceptible to the cat-flea, Ctenocephalides felis felis Bouche (Siphonaptera: Pulicidae), an experimental model was established for evaluating insecticidal treatments on this host. A high establishment rate (76.7-91.8%) was recorded when 60 unfed adult C. felis were placed on ferrets. This provided an adequate infestation for chemotherapeutic evaluation without causing undue discomfort to the host. Twelve ferrets were allocated to two groups matched for sex and individual ability to sustain a flea population. One group was treated topically with an imidacloprid spot-on formulation at a dose rate of 10 mg/kg body-weight on Day 0. All ferrets were infested with C. felis on Days -1, 7, 14, 21 and 28, and flea counts were performed 8 and 24 h post-treatment and one day after each subsequent infestation. Fleas were removed at all but the 8 h count (when they were returned to their host). Flea burdens were reduced by 95.3% (P < 0.001) within 8 h of treatment and 100% efficacy was recorded at 24 h. At 1, 2, 3 and 4 weeks post-treatment, protection against re-infestation was 92.9% (P < 0.001), 55.7% (P < 0.02), 18.3% (NS) and 7.4% (NS), respectively. Thus, at this dose rate, imidacloprid gave excellent efficacy against a resident C. felis population and provided a high level of residual activity for at least one week after treatment.
Day M.j. - One of the best experts on this subject based on the ideXlab platform.
-
Recommendations on vaccination for Latin American small Animal practitioners: A report of the WSAVA Vaccination Guidelines Group
'Foundation for Cellular and Molecular Medicine', 2020Co-Authors: Day M.j., Crawford C., Marcondes M., Squires R.a.Abstract:The World Small Animal Veterinary Association Vaccination Guidelines Group has produced global guidelines for small companion Animal practitioners on best practice in canine and feline vaccination. Recognising that there are unique aspects of veterinary practice in certain geographical regions of the world, the Vaccination Guidelines Group undertook a regional project in Latin America between 2016 and 2019, culminating in the present document. The Vaccination Guidelines Group gathered scientific and demographic data during visits to Argentina, Brazil and Mexico, by discussion with national key opinion leaders, visiting veterinary practices and review of the scientific literature. A questionnaire survey was completed by 1390 veterinarians in five Latin American countries and the Vaccination Guidelines Group delivered continuing education at seven events attended by over 3500 veterinarians. The Vaccination Guidelines Group recognised numerous challenges in Latin America, for example: (1) lack of national oversight of the veterinary profession, (2) extraordinary growth in private veterinary schools of undetermined quality, (3) socioeconomic constraints on client engagement with preventive health care, (4) high regional prevalence of some key infectious diseases (e.g. feline leukaemia virus infection, canine visceral leishmaniosis), (5) almost complete lack of minimal antigen vaccine products as available in other markets, (6) relative lack of vaccine products with extended duration of immunity as available in other markets, (7) availability of vaccine products withdrawn from other markets (e.g. Giardia vaccine) or unique to Latin America (e.g. some Leishmania vaccines), (8) accessibility of vaccines directly by Pet owners or breeders such that vaccination is not delivered under veterinary supervision, (9) limited availability of continuing education in veterinary vaccinology and lack of compulsion for continuing professional development and (10) limited peer‐reviewed published scientific data on small companion Animal infectious diseases (with the exception of leishmaniosis) and lack of support for such academic research. In this document, the Vaccination Guidelines Group summarises the findings of this project and assesses in evidence‐based fashion the scientific literature pertaining to companion Animal vaccine‐preventable diseases in Latin America. The Vaccination Guidelines Group makes some recommendations on undergraduate and postgraduate education and academic research. Recognising that current product availability in Latin America does not permit veterinarians in these countries to vaccinate according to the global World Small Animal Veterinary Association guidelines, the Vaccination Guidelines Group makes a series of “pragmatic” recommendations as to what might be currently achievable, and a series of “aspirational” recommendations as to what might be desirable for the future. The concept of “vaccine husbandry” is addressed via some simple guidelines for the management of vaccine products in the practice. Finally, the Vaccination Guidelines Group emphasises the global trend towards delivery of vaccination as one part of an “annual health check” or “health care plan” that reviews holistically the preventive health care needs of the individual Pet Animal. Latin American practitioners should transition towards these important new practices that are now well embedded in more developed veterinary markets. The document also includes 70 frequently asked questions and their answers; these were posed to the Vaccination Guidelines Group during our continuing education events and small group discussions and should address many of the issues surrounding delivery of vaccination in the Latin American countries. Spanish and Portuguese translations of this document will be made freely available from the on‐line resource pages of the Vaccination Guidelines Group
-
Guidelines for the vaccination of dogs and cats compiled by the Vaccination Guidelines Group (VGG) of the World Small Animal Veterinary Association (WSAVA)
'Wiley', 2016Co-Authors: Day M.j., Horzinek M.c., Schultz R.d., Squires R.a.Abstract:The WSAVA Vaccination Guidelines Group (VGG) was convened in order to develop guidelines for the vaccination of dogs and cats that have global application. The first version of these guidelines was published in 2007 and they were updated in 2010. The present document provides a further updated and expanded version of these international guidelines for the vaccination of small companion Animals and indicates the scientific evidence base on which the recommendations are made. The VGG recognises that the keeping of Pet small Animals is subject to considerable variation in practice and associated economics throughout the world and that vaccination recommendations that might apply to a developed country may not be appropriate for a developing country. These guidelines are not a mandatory edict, but rather should be used by national associations and individual veterinary practices to develop vaccination schedules relevant locally. However, the VGG strongly recommends that wherever possible ALL dogs and cats receive the benefit of vaccination. This not only protects the individual Animal, but provides optimum ‘herd immunity’ that minimises the likelihood of infectious disease outbreaks. With this background in mind, the VGG has defined core vaccines as those which ALL dogs and cats, regardless of circumstances or geographical location, should receive. Core vaccines protect Animals from severe, life-threatening diseases that have global distribution. Core vaccines for dogs are those that protect against canine distemper virus (CDV), canine adenovirus (CAV) and the variants of canine parvovirus type 2 (CPV-2). Core vaccines for cats are those that protect against feline parvovirus (FPV), feline calicivirus (FCV) and feline herpesvirus-1 (FHV-1). In areas of the world where rabies virus infection is endemic, vaccination against this agent should be considered core for both species, even if there is no legal requirement for routine vaccination. The VGG recognizes that maternally-derived antibody (MDA) interferes with the efficacy of most current core vaccines administered to pups and kittens in early life. Because the level of MDA varies among litters, the VGG recommends administration of multiple core vaccine doses to pups and kittens, with the final dose given at 16 weeks or older and followed by a booster at 6- or 12-months of age. In cultural or financial situations where a Pet Animal may only be permitted the benefit of a single vaccination, that vaccination should be with core vaccines at 16 weeks of age or older. The VGG supports the use of simple in-practice tests for determination of seroconversion to the core vaccine components (CDV, CAV, CPV-2 and FPV) following vaccination, for determination of seroprotection in adult dogs and for management of infectious disease outbreaks in shelters. Vaccines should not be given needlessly. Core vaccines should not be given any more frequently than every three years after the 6- or 12-month booster injection following the puppy/kitten series, because the duration of immunity (DOI) is many years and may be up to the lifetime of the Pet. The VGG has defined non-core vaccines as those that are required by only those Animals whose geographical location, local environment or lifestyle places them at risk of contracting specific infections. The VGG has also classified some vaccines as not recommended (where there is insufficient scientific evidence to justify their use) and has not considered a number of minority products which have restricted geographical availability or application. The VGG strongly supports the concept of regular (usually annual) health checks which removes the emphasis from, and client expectation of, annual revaccination. The annual health check may still encompass administration of selected non-core vaccines which should be administered annually, as the DOI for these products is generally 1 year. The VGG has considered the use of vaccines in Animal shelters, again recognising the particular circumstances of such establishments and the financial constraints under which they sometimes operate. The VGG minimum shelter guidelines are simple: that all dogs and cats entering such an establishment should be vaccinated before, or at the time of entry, with core vaccines. Where finances permit, repeated core vaccines should be administered as per the schedules defined in the guidelines and non-core vaccines against respiratory disease may be included. The VGG recognizes the importance of adverse reaction reporting schemes, but understands that these are variably developed in different countries. Wherever possible, veterinarians should be actively encouraged to report all possible adverse events to the manufacturer and/or regulatory authority to expand the knowledge base that drives development of improved vaccine safety. These fundamental concepts proposed by the VGG may be encapsulated in the following statement: We should aim to vaccinate every Animal with core vaccines. Non-core vaccines should be given no more frequently than is deemed necessary
M J Hutchinson - One of the best experts on this subject based on the ideXlab platform.
-
establishment of the cat flea ctenocephalides felis felis on the ferret mustela putorius furo and its control with imidacloprid
Medical and Veterinary Entomology, 2001Co-Authors: M J Hutchinson, D E Jacobs, Norbert MenckeAbstract:As the ferret, Mustela putorius furo L. (Carnivora: Mustelidae), is becoming increasingly popular as a Pet Animal and as it is susceptible to the cat-flea, Ctenocephalides felis felis Bouche (Siphonaptera: Pulicidae), an experimental model was established for evaluating insecticidal treatments on this host. A high establishment rate (76.7-91.8%) was recorded when 60 unfed adult C. felis were placed on ferrets. This provided an adequate infestation for chemotherapeutic evaluation without causing undue discomfort to the host. Twelve ferrets were allocated to two groups matched for sex and individual ability to sustain a flea population. One group was treated topically with an imidacloprid spot-on formulation at a dose rate of 10 mg/kg body-weight on Day 0. All ferrets were infested with C. felis on Days -1, 7, 14, 21 and 28, and flea counts were performed 8 and 24 h post-treatment and one day after each subsequent infestation. Fleas were removed at all but the 8 h count (when they were returned to their host). Flea burdens were reduced by 95.3% (P < 0.001) within 8 h of treatment and 100% efficacy was recorded at 24 h. At 1, 2, 3 and 4 weeks post-treatment, protection against re-infestation was 92.9% (P < 0.001), 55.7% (P < 0.02), 18.3% (NS) and 7.4% (NS), respectively. Thus, at this dose rate, imidacloprid gave excellent efficacy against a resident C. felis population and provided a high level of residual activity for at least one week after treatment.
D H Lloyd - One of the best experts on this subject based on the ideXlab platform.
-
Pet Animals as reservoirs of antimicrobial resistant bacteria
Journal of Antimicrobial Chemotherapy, 2004Co-Authors: Luca Guardabassi, Stefan Schwarz, D H LloydAbstract:Pet Animal numbers have substantially increased in modern society and attention is increasingly devoted to Pet welfare. Because of these changes, antimicrobial agents are frequently used in small Animal veterinary practice, often including antimicrobial preparations used in human medicine, with heavy use of broad-spectrum agents such as aminopenicillins plus clavulanic acid, cephalosporins and fluoroquinolones. Several longitudinal studies conducted at veterinary hospitals have indicated that resistance to various antimicrobial agents has emerged amongst Pet Animal isolates of Staphylococcus intermedius, Escherichia coli and other bacteria, including species with a potential for zoonotic transmission and resistance phenotypes of clinical interest, such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci and multidrug-resistant Salmonella Typhimurium DT104. Based on a review of the current literature, the role of Pets in the dissemination of antimicrobial resistance has been given little attention when compared with that of food Animals. A marked contrast is evident between the current policies on antimicrobial usage in food and companion Animals. Apart from a few countries where limited data on antimicrobial usage and occurrence of resistance in bacteria from Pet Animals are provided, national surveillance programmes only focus on food Animals. However, data on Pet Animals are clearly needed for guiding antimicrobial use policy in small Animal veterinary practice as well as for assessing the risk of transmission of antimicrobial resistance to humans.